Protagonist Therapeutics, Inc. ( PTGX) - Stock Earnings
PTGX Upcoming earnings
Estimated EPS and revenue columns are available to paid members.
| Date | EPS (actual / est.) | Revenue low (est.) | Revenue (actual / est.) | Revenue high (est.) |
|---|---|---|---|---|
| Nov. 5, 2026, midnight | — / — | — | — / — | — |
PTGX Quarterly earnings
Analyst consensus estimates are available to paid members.
| Date | Earnings | Revenue |
|---|---|---|
| 2025Q4 | -44.4 million USD | 7.4 million USD |
| 2026Q1 | 3.8 million USD | 56.4 million USD |
| 2026Q2 | 162.8 million USD | 213.5 million USD |
| 2026Q4 Est. | — | — |
| 2027Q1 Est. | — | — |
| 2027Q2 Est. | — | — |
PTGX Yearly earnings
Analyst consensus estimates are available to paid members.
| Date | Earnings | Revenue |
|---|---|---|
| 2023 | -79.0 million USD | 60.0 million USD |
| 2024 | 275.2 million USD | 434.4 million USD |
| 2025 | -130.1 million USD | 46.0 million USD |
| 2026 Est. | — | — |
PTGX
Price: $138.49
Earnings Per Share: 1.04 USD
P/E Ratio: 140.26
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 966400
Ebitda: -4.9 millionMarket Capitalization: 9.0 billion